Adlai Nortye (ANL)

• Market cap: $62M
• 1 day: -1.19%
• 5 days: -4.05%
• 1 month: -7.26%
• 3 months: 5.73%
• 6 months: -20.57%
• Year to date: -31.97%
• 1 year: -15.31%
• 5 years: -88.93%
• 10 years: -88.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Employees: 123